Edesa biotech, inc.EDSA.US Overview

US StockHealthcare

(No presentation for EDSA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

EDSA Overall Performance

EDSA AI Analysis & Strategy

EDSA Recent Performance

4.11%

Edesa biotech, inc.

0.81%

Avg of Sector

-1.14%

S&P500

EDSA PowerScanner

EDSA Key Information

EDSA Valuation Metrics

EDSA Earnings Table

EDSA Profile

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.